The present study revealed that Bay 73-6691 could ameliorate neurological damage in the CHIP mutation model through a dual ubiquitination–phosphorylation pathway, potentially serving as a candidate drug for treating CHIP-related diseases and thereby offering a new approach for the treatment of related diseases, especially CHIP mutation-related ataxias. This evidence concerns the gene STUB1 and Ataxia.